Guidant
This article was originally published in The Gray Sheet
Executive Summary
Enrollment in the firm's 1,042-patient, 70-center DELIVER trial to evaluate effectiveness of the paclitaxel-coated Multi-Link Penta stent compared to an uncoated version is expected to begin in mid-November following submission of an investigational device exemption application, announced Oct. 8. Nine-month follow-up is expected by the fourth quarter of 2002. Separately, Guidant announces CE mark approval for the Insignia pacemaker line, European launch of the Acculink carotid stent system and worldwide launch of the second-generation Viatrac 14 Plus peripheral dilatation catheter for treatment of blockages of peripheral arteries